FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1689-1690 May 27, 1999 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article

To the Editor: In compliance with the Journal's editorial rules regarding disclosure of affiliations and according to my understanding of those rules, I provided a single institutional affiliation when I submitted a letter to the editor concerning hormonal treatment of prostate cancer (March 11 issue).¹ At the request of the Editors after the submission of my letter, I am providing the following information: in addition to being clinical professor of medicine (part-time) at Harvard Medical School and the Beth Israel Deaconess Medical Center, I am also chief medical officer of Praecis Pharmaceuticals, a company involved in the development of . . . [Full Text of this Article]

References

Related Letters:

Hormonal Treatment of Prostate Cancer
Garnick M. B., Eisenberger M., Blumenstein B. A.
Extract | Full Text  
N Engl J Med 1999; 340:812-813, Mar 11, 1999. Correspondence

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.